Master uterine artery embolization with this evidence-based protocol covering indications, imaging parameters, embolic selection, outcomes, and follow-up for radiologists.

Uterine Artery Embolization: Complete 2026 Protocol for Radiologists

Introduction

Uterine artery embolization is a minimally invasive image-guided procedure that has revolutionized the management of symptomatic uterine fibroids and other gynecologic vascular conditions. By selectively occluding the uterine arteries with calibrated embolic agents, interventional radiologists can achieve significant symptom relief while preserving the uterus. This evidence-based protocol provides a comprehensive framework for patient selection, technical execution, and post-procedural care.

The procedure demands precise angiographic technique, thorough knowledge of pelvic vascular anatomy, and careful patient counseling regarding fertility implications and post-embolization syndrome. As uterine artery embolization continues to gain acceptance as a first-line alternative to hysterectomy, standardized protocols ensure consistent outcomes across practice settings.

Clinical indications and patient selection

The primary indication for uterine artery embolization remains symptomatic uterine fibroids refractory to medical management. Patients typically present with menorrhagia, bulk-related pelvic pressure, urinary frequency, or chronic pelvic pain. Uterine artery embolization offers a uterus-preserving alternative to hysterectomy and myomectomy for women who have completed childbearing or wish to retain fertility potential.

Beyond fibroids, uterine artery embolization effectively treats uterine adenomyosis, although durability is inferior compared with fibroid outcomes. Other accepted indications for uterine artery embolization include postpartum hemorrhage, cervical ectopic pregnancy, and uterine arteriovenous malformations. Patient selection requires multidisciplinary consultation with gynecology, particularly when fertility preservation is a priority.

Ideal candidates demonstrate a clear fibroid burden on cross-sectional imaging with corresponding clinical symptoms. Contraindications must be excluded through comprehensive pre-procedural evaluation, including pregnancy testing, pelvic imaging, and assessment of renal function and coagulation status.

Pre-procedural workup and preparation

Pre-procedural preparation for uterine artery embolization begins with contrast-enhanced pelvic MRI to characterize fibroid location, size, and vascularity. The uterine fibroid symptom and health-related quality of life (UFS-QOL) questionnaire establishes baseline symptom severity and enables objective post-procedural comparison. Laboratory evaluation includes complete blood count, comprehensive metabolic panel, coagulation studies, and serum pregnancy testing.

Patients should be nil per os for six hours before the procedure. Prophylactic antibiotics covering vaginal flora are administered according to Society of Interventional Radiology guidelines, typically a third-generation cephalosporin combined with metronidazole. A Foley catheter facilitates bladder decompression and improves pelvic visualization during angiography.

Informed consent must address the risk of post-embolization syndrome, ovarian failure, nontarget embolization, and the potential need for repeat intervention or hysterectomy. For patients desiring future fertility, detailed counseling regarding pregnancy outcomes and miscarriage risk is mandatory.

Vascular access and catheterization technique

Vascular access is obtained via the common femoral artery using a four to five French vascular sheath. A unilateral puncture with Waltman loop technique often permits bilateral uterine artery catheterization, though bilateral femoral access remains an acceptable alternative. Aortic bifurcation anatomy and prior pelvic surgery may influence access site selection.

Selective catheterization of the uterine arteries requires reverse curve or cobra-shaped diagnostic catheters. The left uterine artery typically arises from the anterior division of the internal iliac artery and courses medially toward the uterus. The right uterine artery follows a similar path but may be more challenging to cannulate due to acute angulation from the aortic bifurcation.

Cone-beam computed tomography (CBCT) has emerged as an invaluable adjunct for uterine artery embolization, identifying ovarian artery origins and mapping fibroid perfusion territories. This technology reduces the risk of nontarget embolization and improves technical precision during microcatheter positioning for uterine artery embolization.

Imaging parameters and contrast protocol

Digital subtraction angiography remains the cornerstone of intra-procedural imaging. Pelvic aortography is performed at two to three frames per second using fifteen to twenty milliliters of non-ionic contrast injected at ten to fifteen milliliters per second. This initial survey identifies variant anatomy, ovarian artery origins, and the dominant feeding vessels.

Selective uterine arteriography utilizes three to five milliliters of contrast at two to three milliliters per second. Roadmap fluoroscopy facilitates microcatheter navigation into distal branches supplying the dominant fibroid. CBCT angiography requires six to eight milliliters at two milliliters per second and provides three-dimensional perfusion mapping.

Post-embolization angiography confirms stasis within the target vessels and excludes nontarget occlusion. Flat-panel computed tomography may be obtained when concern exists for ovarian artery embolization or incomplete fibroid coverage.

Embolic agents and equipment selection

Five French Cobra, Roberts, or Simmons diagnostic catheters provide stable platform access for uterine artery cannulation. A two-point-four to two-point-eight French microcatheter is advanced coaxially for superselective embolization when tortuous anatomy or distal targeting is required. Microwires range from zero-point-zero-one-four to zero-point-zero-one-eight inches.

Calibrated tris-acryl gelatin microspheres represent the preferred embolic agent for uterine artery embolization. Embosphere five hundred to seven hundred micrometers or seven hundred to nine hundred micrometers achieve optimal vessel occlusion while minimizing passage through dangerous anastomoses. Polyvinyl alcohol particles and spherical embolics are acceptable alternatives, though particles smaller than five hundred micrometers should be avoided to prevent nontarget ovarian embolization.

Additional equipment includes a three-way stopcock, extension tubing, and a dedicated embolization syringe for controlled particle delivery. Pressure bags and in-line filters prevent air embolization and ensure homogeneous particle suspension.

Procedural workflow and embolization endpoints

The uterine artery embolization workflow begins with pelvic aortography to define vascular anatomy and identify ovarian artery origins. The uterine artery is selectively catheterized, and a microcatheter is advanced to the horizontal segment if superselective embolization is planned. Test injections confirm stable catheter position away from the cervicovaginal branch and ovarian anastomoses.

Embolization proceeds slowly with calibrated microspheres suspended in diluted contrast. The endpoint is near-stasis with sluggish antegrade flow, not complete occlusion. Aggressive embolization risks reflux into ovarian, vaginal, or internal pudendal collaterals. Continuous fluoroscopic monitoring with blank roadmapping ensures controlled delivery.

Bilateral uterine artery embolization is performed in the same session for symmetric fibroid burden. Unilateral uterine artery embolization may suffice when symptoms localize to one side or when contralateral access is precluded. Final angiography documents the embolization endpoint and excludes nontarget vessel occlusion.

Post-embolization syndrome management

Post-embolization syndrome is expected in the majority of patients and typically manifests within twenty-four to forty-eight hours. Symptoms include pelvic pain, low-grade fever, malaise, nausea, and leukocytosis. The syndrome reflects ischemic necrosis of fibroid tissue and transient myometrial inflammation.

Pain management requires multimodal analgesia including patient-controlled analgesia pumps or epidural anesthesia for the first twenty-four hours. Nonsteroidal anti-inflammatory drugs reduce inflammation and opioid requirements. Antiemetics address nausea, while intravenous hydration supports renal function and contrast clearance.

Most patients require overnight observation and discharge within twenty-four to forty-eight hours. Oral analgesics are continued for seven to ten days. Patients should be counseled that cramping may persist for one to two weeks as fibroids involute.

Expected outcomes and clinical success rates

Clinical success following uterine artery embolization ranges from eighty to ninety percent at one year, with sustained symptom relief in approximately seventy percent of patients at five years. Fibroid volume reduction averages forty to sixty percent at six months on follow-up magnetic resonance imaging. Menorrhagia improvement occurs in eighty-five to ninety-five percent of appropriately selected patients.

Quality-of-life scores improve significantly within three months after uterine artery embolization and remain durable for the majority of patients. The FEMME randomized controlled trial demonstrated comparable quality-of-life outcomes between uterine artery embolization and myomectomy at two years, with shorter hospitalization and faster return to normal activities in the embolization cohort.

Reintervention rates range from twenty to twenty-five percent at five years, with repeat embolization, myomectomy, or hysterectomy representing standard salvage options. Younger age and larger baseline fibroid volume are independent predictors of treatment failure and recurrence.

Complications and risk mitigation

Post-embolization syndrome is the most common adverse event after uterine artery embolization and is considered an expected consequence rather than a true complication. Ovarian failure occurs in one to five percent of patients after uterine artery embolization, with risk increasing significantly after age forty-five. The mechanism involves nontarget embolization via uterine-ovarian anastomoses or direct ovarian artery occlusion.

Fibroid expulsion affects five to ten percent of patients, particularly those with submucosal fibroids. While often asymptomatic, expulsion may cause severe cramping, vaginal discharge, or sepsis requiring hysteroscopic removal. Pelvic infection and endometritis occur in one to two percent of cases and demand prompt antibiotic therapy.

Nontarget embolization to the labia, buttocks, or lower extremities is rare but documented when dangerous anastomoses are unrecognized. Uterine necrosis represents a catastrophic complication requiring hysterectomy and is more common in postpartum hemorrhage protocols than in elective fibroid embolization.

Contraindications

Absolute contraindications to uterine artery embolization include confirmed pregnancy, active pelvic infection, and suspected uterine malignancy. Asymptomatic fibroids do not warrant intervention. Severe iodinated contrast allergy that cannot be premedicated and uncorrectable coagulopathy preclude safe angiographic access.

Relative contraindications encompass the desire for future fertility, which remains controversial given variable pregnancy outcomes. Pedunculated subserosal fibroids with stalk diameter less than fifty percent of the tumor diameter carry torsion and separation risk. Large fibroids exceeding ten centimeters may achieve inferior volume reduction compared with surgical alternatives.

The presence of a common arterial supply to the uterus and ovaries that cannot be bypassed represents a significant relative contraindication, particularly in women over forty-five years of age. Prior pelvic radiation and extensive pelvic adhesions may compromise vascular access and procedural safety.

Follow-up protocol and imaging surveillance

Follow-up imaging after uterine artery embolization includes contrast-enhanced pelvic MRI obtained at three to six months to assess fibroid devascularization and volume reduction. Complete necrosis appears as non-enhancing low-signal tissue on T1-weighted imaging. Residual enhancement suggests viable fibroid tissue and predicts symptom recurrence after uterine artery embolization.

Clinical follow-up occurs at one, three, six, and twelve months using the UFS-QOL questionnaire and pelvic examination. Patients should report any fever, worsening pain, or malodorous discharge immediately. Hysteroscopic evaluation is indicated when submucosal fibroid expulsion is suspected.

For patients achieving satisfactory outcomes, annual surveillance is sufficient. Those with persistent symptoms or incomplete necrosis may be candidates for repeat embolization or alternative intervention. Multidisciplinary review with gynecology ensures comprehensive long-term management.

Conclusion

Uterine artery embolization stands as a cornerstone of modern interventional gynecology, offering durable symptom relief with preserved uterine anatomy. Success depends on rigorous patient selection, meticulous angiographic technique, and proactive management of post-embolization syndrome after uterine artery embolization. Radiologists must maintain expertise in pelvic vascular anatomy and embolic endpoint determination.

As evidence accumulates supporting expanded indications and refined embolic technologies, uterine artery embolization will likely assume an increasingly prominent role in fibroid management algorithms. Institutional protocols for uterine artery embolization should incorporate standardized imaging, patient-reported outcomes, and long-term surveillance to maximize clinical benefit. For departments seeking to optimize workflow efficiency, integrated contrast and consumable calculators support consistent protocol adherence.

References